Drug repositioning in pulmonary arterial hypertension: challenges and opportunities

Despite many advances in medical therapy for pulmonary arterial hypertension (PAH) over the past 20 years, long-term survival is still poor. Novel therapies which target the underlying pathology of PAH and which could be added to current vasodilatory therapies to halt disease progression and potenti...

Descripción completa

Detalles Bibliográficos
Autores principales: Grinnan, Daniel, Trankle, Cory, Andruska, Adam, Bloom, Bruce, Spiekerkoetter, Edda
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2019
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6852366/
https://www.ncbi.nlm.nih.gov/pubmed/30729869
http://dx.doi.org/10.1177/2045894019832226

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6852366/
https://www.ncbi.nlm.nih.gov/pubmed/30729869
http://dx.doi.org/10.1177/2045894019832226

Ejemplares similares